Medical cannabis authorization was linked to higher risk of emergency visits for depression
In a propensity-matched cohort study, patients authorized for medical cannabis had a higher risk of emergency department visits and hospitalization for depressive disorders compared to matched controls.
Quick Facts
What This Study Found
Medical cannabis users had significantly higher rates of ED visits and hospitalization for depressive disorders than propensity-matched controls who did not receive medical cannabis authorization.
Key Numbers
Propensity score-matched cohort. Medical cannabis authorization associated with increased risk of ED visits and hospitalization for depressive disorders.
How They Did This
Retrospective longitudinal cohort study using propensity score matching. Compared patients who received medical cannabis authorization with matched controls on rates of ED visits and hospitalization for depressive disorders.
Why This Research Matters
Medical cannabis is increasingly used for conditions that overlap with depression. If cannabis authorization is associated with increased depression-related emergencies, it has important implications for patient monitoring and informed consent.
The Bigger Picture
The relationship between cannabis and depression is complex: some people use cannabis to manage depression, but cannabis may also worsen or unmask depressive symptoms. This study suggests the net effect at the population level may not be beneficial.
What This Study Doesn't Tell Us
Observational design even with propensity matching cannot establish causation. People who seek medical cannabis may have more severe or treatment-resistant conditions. Cannot determine whether cannabis caused, worsened, or simply coincided with depression. Propensity matching may not capture all relevant differences.
Questions This Raises
- ?Does the depression risk differ by cannabis formulation or indication?
- ?Would prospective monitoring of mental health in medical cannabis patients prevent emergency presentations?
Trust & Context
- Key Stat:
- Medical cannabis authorization linked to higher depression-related emergency care
- Evidence Grade:
- Propensity-matched retrospective cohort is stronger than unmatched observational data, but residual confounding likely remains.
- Study Age:
- Published 2023.
- Original Title:
- Risk of depressive disorders associated with medical cannabis authorization: A propensity score matched cohort study.
- Published In:
- Psychiatry research, 320, 115047 (2023)
- Authors:
- Yana, Jerry Liwono, Lee, Cerina(7), Eurich, Dean T(13), Dyck, Jason R B, Hanlon, John G, Zongo, Arsène
- Database ID:
- RTHC-05041
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Can medical cannabis make depression worse?
This study found that people authorized for medical cannabis had more emergency visits and hospitalizations for depression than matched controls. However, it cannot prove cannabis caused the depression. People who seek medical cannabis may have more complex health situations that independently increase depression risk.
Should people with depression avoid medical cannabis?
This study adds a cautionary note but does not definitively answer the question. The relationship between cannabis and depression likely depends on many factors including the specific cannabis product, dose, reason for use, and individual biology. Mental health monitoring during medical cannabis use seems prudent.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05041APA
Yana, Jerry Liwono; Lee, Cerina; Eurich, Dean T; Dyck, Jason R B; Hanlon, John G; Zongo, Arsène. (2023). Risk of depressive disorders associated with medical cannabis authorization: A propensity score matched cohort study.. Psychiatry research, 320, 115047. https://doi.org/10.1016/j.psychres.2022.115047
MLA
Yana, Jerry Liwono, et al. "Risk of depressive disorders associated with medical cannabis authorization: A propensity score matched cohort study.." Psychiatry research, 2023. https://doi.org/10.1016/j.psychres.2022.115047
RethinkTHC
RethinkTHC Research Database. "Risk of depressive disorders associated with medical cannabi..." RTHC-05041. Retrieved from https://rethinkthc.com/research/yana-2023-risk-of-depressive-disorders
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.